Foley Hoag advised Genialis, a computational precision medicine company, in its $13M Series A financing led by Debiopharm Innovatoin Fund and Taiwania Capital with participation from previous investors First Star Ventures, Redalpine Venture Partners, Pikas, and P5 Health Ventures.
Genialis has plans to expand its proprietary ResponderIDTM machine learning platform for clinical and translational research, and to build out its comprehensive collection of clinically validated biomarker models to provide pinpoint diagnoses for virtually every cancer patient.
Genialis is growing its teams in both the U.S. and Slovenia across its business, operations, life science and data science functions, and expanding its advisory boards.
Foley Hoag attorneys Patrick Connolly and Sarah Ropiak represented Genialis in the transaction.
About Foley Hoag
Foley Hoag is an award-winning, mid-sized, international law firm that focuses on innovative industries and high-stakes litigation. The diverse backgrounds, perspectives and experiences of our lawyers and business services professionals contribute to the exceptional service we deliver to clients. We have offices in Boston, Denver, New York, Paris and Washington, D.C. For more information, visit www.foleyhoag.com.
